Oral Immunization of Mice with Gamma-Irradiated Brucella neotomae Induces Protection against Intraperitoneal and Intranasal Challenge with Virulent B. abortus 2308
Open Access
- 16 September 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9) , e107180
Abstract
Brucella spp. are Gram-negative, facultative intracellular coccobacilli that cause one of the most frequently encountered zoonosis worldwide. Humans naturally acquire infection through consumption of contaminated dairy and meat products and through direct exposure to aborted animal tissues and fluids. No vaccine against brucellosis is available for use in humans. In this study, we tested the ability of orally inoculated gamma-irradiated B. neotomae and B. abortus RB51 in a prime-boost immunization approach to induce antigen-specific humoral and cell mediated immunity and protection against challenge with virulent B. abortus 2308. Heterologous prime-boost vaccination with B. abortus RB51 and B. neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the production of serum and mucosal antibodies specific to the smooth LPS. The elicited serum antibodies included the isotypes of IgM, IgG1, IgG2a, IgG2b and IgG3. All oral vaccination regimens induced antigen-specific CD4+ and CD8+ T cells capable of secreting IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae showed the highest level of resistance against virulent B. abortus 2308 colonization in spleen and liver. Experiments with different doses of B. neotomae showed that all tested doses of 109, 1010 and 1011 CFU-equivalent conferred significant protection against the intra-peritoneal challenge. However, a dose of 1011 CFU-equivalent of B. neotomae was required for affording protection against intranasal challenge as shown by the reduced bacterial colonization in spleens and lungs. Taken together, these results demonstrate the feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to induce protection against respiratory and systemic infections with virulent Brucella.Keywords
This publication has 26 references indexed in Scilit:
- Protective Live Oral Brucellosis Vaccines Stimulate Th1 and Th17 Cell ResponsesInfection and Immunity, 2011
- Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challengeVaccine, 2011
- Towards aBrucellavaccine for humansFEMS Microbiology Reviews, 2010
- Brucellosis: The case for live, attenuated vaccinesVaccine, 2009
- Brucellosis Vaccines: Assessment of Brucella melitensis Lipopolysaccharide Rough Mutants Defective in Core and O-Polysaccharide Synthesis and ExportPLOS ONE, 2008
- Human brucellosisThe Lancet Infectious Diseases, 2007
- Evaluation of Protection Afforded by Brucella abortus and Brucella melitensis Unmarked Deletion Mutants Exhibiting Different Rates of Clearance in BALB/c MiceInfection and Immunity, 2006
- Induction of Antigen-Specific Th1-Type Immune Responses by Gamma-Irradiated RecombinantBrucella abortusRB51Clinical and Vaccine Immunology, 2005
- Oral Vaccination withBrucella melitensisWR201 Protects Mice against Intranasal Challenge with VirulentBrucella melitensis16MInfection and Immunity, 2004
- Brucella abortusRB51 Induces Protection in Mice Orally Infected with the Virulent StrainB. abortus2308Infection and Immunity, 2003